October 30, 2026

News, minutes after it breaks

Business
Latest
Packers' Jacobs says TD celebration was ode to gospel song, not mocking arrestIran claims four tankers struck mines in Hormuz as strike fears grow after U.S. midtermsSurvivors of Spain’s worst train crashes urge action after latest disasterFrench presidential hopeful Édouard Philippe quizzed in embezzlement caseUS midterms: 4 days to go – What the polls say as Trump cancels two ralliesHow talking about Man Utd's cycle of doom became an industryHyrox athlete who soiled herself in race tells BBC she put others at risk but says backlash was traumaticSyrians struggle with soaring prices as crisis challenges post-Assad recoveryPackers' Jacobs says TD celebration was ode to gospel song, not mocking arrestIran claims four tankers struck mines in Hormuz as strike fears grow after U.S. midtermsSurvivors of Spain’s worst train crashes urge action after latest disasterFrench presidential hopeful Édouard Philippe quizzed in embezzlement caseUS midterms: 4 days to go – What the polls say as Trump cancels two ralliesHow talking about Man Utd's cycle of doom became an industryHyrox athlete who soiled herself in race tells BBC she put others at risk but says backlash was traumaticSyrians struggle with soaring prices as crisis challenges post-Assad recovery

Home  / Business

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Business CNBC
Image: CNBC

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

CNBC reported this story. Read the full report on cnbc.com →

This is a short summary. CNBC wrote and published the full report.

Continue on cnbc.com →

More in Business

Leave a Reply

Your email address will not be published. Required fields are marked *